Last reviewed · How we verify
SM-13496
SM-13496 is a selective and potent inhibitor of the sodium-glucose cotransporter 2 (SGLT2).
SM-13496 is a selective and potent inhibitor of the sodium-glucose cotransporter 2 (SGLT2). Used for Treatment of type 2 diabetes.
At a glance
| Generic name | SM-13496 |
|---|---|
| Also known as | Lurasidone HCl, Lurasidone |
| Sponsor | Sumitomo Pharma Co., Ltd. |
| Drug class | SGLT2 inhibitor |
| Target | SGLT2 |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
By inhibiting SGLT2, SM-13496 reduces glucose reabsorption in the kidneys, leading to increased glucose excretion in the urine and lowering blood glucose levels. This mechanism is particularly beneficial for patients with type 2 diabetes.
Approved indications
- Treatment of type 2 diabetes
Common side effects
- Increased risk of genital mycotic infections
- Increased risk of urinary tract infections
- Hypotension
Key clinical trials
- An Exploratory Analysis of Immune and Inflammatory Response Associated With Clozapine (PHASE4)
- Sequential Multiple Assignment Randomized Trial for Bipolar Depression (PHASE4)
- A Randomized, Double-Blind Controlled Comparison of NRX-101 vs. Placebo for Adults Being Treated With Transcranial Magnetic Stimulation for Treatment Resistant Depression (PHASE2, PHASE3)
- Maternal And Infant Antipsychotic Study
- A Study to Assess Stroke Risk Among Users of Typical Versus Atypical Antipsychotics Stratified by Broad Age Group
- Sleep Quality, Cognitive Performance, and Computerized Cognitive Training
- Impact of Aripiprazole Once Monthly Medications on Changes in Brain Structure and Metabolism (PHASE4)
- High Dose Lurasidone for Patients With Treatment Resistant Schizophrenia (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SM-13496 CI brief — competitive landscape report
- SM-13496 updates RSS · CI watch RSS
- Sumitomo Pharma Co., Ltd. portfolio CI